The role of neurogenic inflammation and CGRP in migraine headache.

Recent research has significantly changed how we understand migraines. It began with the discovery of calcitonin gene-related peptide (CGRP). This peptide is key in the process called neurogenic inflammation. This inflammation occurs when specialized sensory neurons are activated. When these neurons are injured, they can send signals that cause pain. These signals can also make other pain-sensing neurons more sensitive. CGRP is the important substance released during this process. It connects early research on pain to current treatment options. New treatments targeting CGRP or its receptor have emerged. These include monoclonal antibodies and small molecule antagonists. They aim to reduce migraine frequency and severity. The understanding of CGRP has opened doors for more effective therapies. This research highlights the biological mechanisms behind migraines. It lays the groundwork for better migraine management in the future. Clinical relevance: This research indicates that targeting CGRP may lead to more effective migraine treatments.